266 related articles for article (PubMed ID: 34518534)
1. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A; Deshpande A; Feng Y; Finlay D; Lee JS; Lazar I; Fabre B; Li Y; Fujita Y; Zhang T; Yin J; Pass I; Livneh I; Jeremias I; Burian C; Mason JR; Almog R; Horesh N; Ofran Y; Brown K; Vuori K; Jackson M; Ruppin E; Deshpande AJ; Ronai ZA
Nat Commun; 2021 Sep; 12(1):5397. PubMed ID: 34518534
[TBL] [Abstract][Full Text] [Related]
2. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
4. The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1.
Yang Q; Chen X; Zhang Y; Hu S; Hu F; Huang Y; Ma T; Hu H; Tian H; Tian S; Ji YX; She ZG; Zhang P; Zhang XJ; Hu Y; Yang H; Yuan Y; Li H
Hepatology; 2021 Dec; 74(6):3018-3036. PubMed ID: 34272738
[TBL] [Abstract][Full Text] [Related]
5. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
[TBL] [Abstract][Full Text] [Related]
6. Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis.
Fujita Y; Khateb A; Li Y; Tinoco R; Zhang T; Bar-Yoseph H; Tam MA; Chowers Y; Sabo E; Gerassy-Vainberg S; Starosvetsky E; James B; Brown K; Shen-Orr SS; Bradley LM; Tessier PA; Ronai ZA
Cell Rep; 2018 Sep; 24(12):3296-3311.e6. PubMed ID: 30232010
[TBL] [Abstract][Full Text] [Related]
7. Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia.
Salik B; Yi H; Hassan N; Santiappillai N; Vick B; Connerty P; Duly A; Trahair T; Woo AJ; Beck D; Liu T; Spiekermann K; Jeremias I; Wang J; Kavallaris M; Haber M; Norris MD; Liebermann DA; D'Andrea RJ; Murriel C; Wang JY
Cancer Cell; 2020 Aug; 38(2):263-278.e6. PubMed ID: 32559496
[TBL] [Abstract][Full Text] [Related]
8. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
9. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Stuani L; Sabatier M; Saland E; Cognet G; Poupin N; Bosc C; Castelli FA; Gales L; Turtoi E; Montersino C; Farge T; Boet E; Broin N; Larrue C; Baran N; Cissé MY; Conti M; Loric S; Kaoma T; Hucteau A; Zavoriti A; Sahal A; Mouchel PL; Gotanègre M; Cassan C; Fernando L; Wang F; Hosseini M; Chu-Van E; Le Cam L; Carroll M; Selak MA; Vey N; Castellano R; Fenaille F; Turtoi A; Cazals G; Bories P; Gibon Y; Nicolay B; Ronseaux S; Marszalek JR; Takahashi K; DiNardo CD; Konopleva M; Pancaldi V; Collette Y; Bellvert F; Jourdan F; Linares LK; Récher C; Portais JC; Sarry JE
J Exp Med; 2021 May; 218(5):. PubMed ID: 33760042
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
12. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
Hao C; Shao X; Song J; Peng M; Lao Y; Mack R; Zhang L; Wei W; Liu N; Wang T; Wu Y; Feng L; Yin L; Wang S; Sun X; Chen S; Zhang J; Li B
Biochem Biophys Res Commun; 2022 Mar; 596():36-42. PubMed ID: 35108652
[TBL] [Abstract][Full Text] [Related]
13. E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING.
Yang LL; Xiao WC; Li H; Hao ZY; Liu GZ; Zhang DH; Wu LM; Wang Z; Zhang YQ; Huang Z; Zhang YZ
Cell Death Dis; 2022 Oct; 13(10):889. PubMed ID: 36270989
[TBL] [Abstract][Full Text] [Related]
14. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
16. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
Ye P; Zhao L; McGirr C; Gonda TJ
Cancer Lett; 2014 Feb; 343(1):98-106. PubMed ID: 24075958
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.
Bromberg KD; Kluger HM; Delaunay A; Abbas S; DiVito KA; Krajewski S; Ronai Z
Cancer Res; 2007 Sep; 67(17):8172-9. PubMed ID: 17804730
[TBL] [Abstract][Full Text] [Related]
19. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
Kim JK; Kan G; Mao Y; Wu Z; Tan X; He H; Lee C
Mol Oncol; 2020 Feb; 14(2):329-346. PubMed ID: 31782885
[TBL] [Abstract][Full Text] [Related]
20. Regulation of ATG4B stability by RNF5 limits basal levels of autophagy and influences susceptibility to bacterial infection.
Kuang E; Okumura CY; Sheffy-Levin S; Varsano T; Shu VC; Qi J; Niesman IR; Yang HJ; López-Otín C; Yang WY; Reed JC; Broday L; Nizet V; Ronai ZA
PLoS Genet; 2012; 8(10):e1003007. PubMed ID: 23093945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
